Cannabidiol

# Research Output: Cannabidiol (CBD)

**PSX ID:** PSX-0127 | **Slug:** cbd | **Generation Provenance:** 031b74e3-2906-4fda-910f-2619ce212261
**Research Date:** 2026-05-06

---

## Chemical Identity

**PubChem CID:** 644019 (verified via API)
**Molecular Formula:** C₂₁H₃₀O₂
**Molecular Weight:** 314.5 g/mol
**InChIKey:** QHMBSVQNZZTUGM-ZWKOTPCHSA-N
**IUPAC Name:** 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
**CAS Number:** 13956-29-1

**Stereochemistry:** CBD is chiral. The naturally occurring form is (-)-CBD, with (1R,6R) configuration at the two stereocenters — consistent with the systematic name in the brief's seed data. The unnatural (+)-CBD enantiomer has been used in research and exhibits distinct pharmacology, including substantially higher affinity at CB1 and CB2 receptors (Bisogno et al. 2001 [Ref 3]). All clinical and most preclinical data refer to (-)-CBD unless otherwise noted.

**Seed Data Cross-Check:** The brief's systematic name (2-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol) matches the IUPAC name returned by PubChem (minor difference in parentheses placement, not chemically significant). The PubChem CID field was blank in the seed data — it is 644019. SMILES and molecular formula fields were blank in the seed data and are now confirmed. No contradictions found between seed chemical data and PubChem record.

**Physical Properties (from literature):** CBD is a highly lipophilic compound (LogP ~6.3), practically insoluble in water, soluble in ethanol, methanol, and lipid-based solvents. This lipophilicity drives the formulation challenges and the marked food effect on bioavailability (McGilveray 2005 [Ref 56]; Grotenhermen 2003 [Ref 5]).

---

## Pharmacology

### Receptor Binding and Mechanisms of Action

CBD is a polypharmacological compound acting at multiple molecular targets. It does not act primarily through CB1 or CB2 cannabinoid receptors in the traditional agonist sense.

**CB1 Receptor (Negative Allosteric Modulator — NAM):**
CBD is currently best characterized as a CB1 negative allosteric modulator (NAM), not a direct agonist or inverse agonist. In HEK293T cells, CBD showed no intrinsic activity at CB1 and marginally reduced orthosteric G-protein signaling, consistent with indirect interaction (AlAli et al. 2026 [Ref 16]). Earlier work by Pertwee (2007 [Ref 2]) characterized CBD as displaying "unexpectedly high potency as an antagonist of CB1/CB2 receptor agonists." The brief's classification as "CB1 negative allosteric modulator" is consistent with current evidence.

**CB2 Receptor:**
CBD antagonizes CB2 receptor agonists. Pertwee (2007 [Ref 2]) noted CBD's manner of interacting with CB2 receptors "provides a possible explanation for its ability to inhibit evoked immune cell migration." Ki values vary by study; CBD has substantially lower affinity for CB2 than THC. The (+)-CBD enantiomer, not the natural form, shows high CB1/CB2 affinity (Bisogno et al. 2001 [Ref 3]).

**TRPV1 (Transient Receptor Potential Vanilloid Type 1):**
CBD activates TRPV1 with EC50 = 3.2–3.5 µM, with maximal effect ~67–70% of ionomycin response, comparable to capsaicin (Bisogno et al. 2001 [Ref 3]). CBD also desensitizes TRPV1 to subsequent capsaicin challenge (Bisogno et al. 2001 [Ref 3]). CBD additionally activates and desensitizes TRPV2, TRPA1, and TRPM8 (De Petrocellis et al. 2011 [Ref 33]), which is relevant to analgesic and anti-inflammatory effects.

**5-HT₁A Receptor (Serotonin 1A):**
CBD is a partial agonist at the human 5-HT₁A receptor. Russo et al. (2005 [Ref 19]) demonstrated that CBD displaces [³H]8-OH-DPAT from cloned human 5-HT₁A receptors in a concentration-dependent manner and increases [³⁵S]GTPγS binding (agonist profile). The pKi for CBD at human brain 5-HT₁A receptors is 4.29–4.47 (hippocampus) and 4.67–4.74 (temporal neocortex), with higher concentrations (100 µM) producing inverse agonism at Gi/o proteins (Martínez-Aguirre et al. 2020 [Ref 20]). In silico modeling suggests CBD binds the orthosteric site and functions as a partial agonist (Yap et al. 2026 [Ref 18]). This activity underlies CBD's anxiolytic, antiemetic, and antipsychotic effects (Mandolini et al. 2018 [Ref 13]).

**GPR55 (Antagonist):**
CBD is a GPR55 antagonist — this mechanism contributes to its antiseizure activity by reducing neuronal excitability and suppressing epileptiform activity. GPR55 antagonism has been identified as one of the CB1/CB2-independent antiseizure mechanisms (Na and Lee 2025 [Ref 6]; Pesántez Ríos et al. 2025 [Ref 22]).

**Adenosine System (Reuptake Inhibitor):**
CBD inhibits the synaptic uptake of adenosine via the equilibrative nucleoside transporter, raising extracellular adenosine levels. This is a CB1-independent mechanism confirmed in rat striatal synaptosomes (Pandolfo et al. 2011 [Ref 21]). Elevated adenosine exerts anti-inflammatory and antiseizure effects, contributing to CBD's therapeutic profile.

**Endocannabinoid System (FAAH Inhibition / Anandamide):**
CBD weakly inhibits fatty acid amide hydrolase (FAAH; IC50 ~27.5 µM) and inhibits anandamide (AEA) cellular uptake (IC50 ~22 µM) (Bisogno et al. 2001 [Ref 3]). By moderately inhibiting AEA degradation, CBD elevates anandamide signaling. A double-blind RCT in schizophrenia showed CBD treatment significantly increased serum anandamide levels, which correlated with clinical improvement (Leweke et al. 2012 [Ref 4]). De Petrocellis et al. (2011 [Ref 33]) confirmed CBD inhibits FAAH specifically among cannabinoids tested.

**Pregnane X Receptor (PXR) — CYP Induction:**
CBD is an agonist at human PXR (hPXR), activating it 23-fold at 10 µM with minimum effective concentration of 0.3 µM (Lau and Chang 2026 [Ref 17]). PXR activation underlies CYP3A4 induction and is relevant to drug-drug interactions.

**Summary of Pharmacological Class:** CBD's multi-target profile encompasses CB1 NAM, CB2 antagonist, TRPV1/TRPV2/TRPA1 agonist and desensitizer, 5-HT₁A partial agonist, GPR55 antagonist, adenosine reuptake inhibitor, and weak FAAH inhibitor. The "Ion channel modulator" and "Serotonin 1A receptor agonist" and "TRPV1 agonist" designations in the seed data are confirmed and accurate.

### Pharmacokinetics

**Oral Bioavailability:** Low and highly variable — typically 6–20% for oil-based formulations in humans. CBD is highly lipophilic, undergoes extensive first-pass hepatic metabolism, and is poorly water-soluble. A pig lymphatic transport model found oral bioavailability of ~6.1% for sesame oil and 9.2% for nanoemulsion formulations (Rizov et al. 2026 [Ref 8 via pmid 41459703]).

**Food Effect:** High-fat meals dramatically increase CBD absorption. EFSA confirmed "CBD's bioavailability is variable, influenced by delivery matrix and food intake" (Turck et al. 2026 [Ref 7]). The clinical dosing recommendation for Epidiolex specifies administration with food.

**Tmax:** Oral administration yields Tmax of approximately 1.5–5 hours depending on formulation and fed/fasted state. The seed data notes come_up of 15–30 minutes, which may reflect subjective onset of anxiolytic effects rather than Cmax.

**Volume of Distribution:** Very large, reflecting high lipophilicity and extensive tissue distribution. Crosses the blood-brain barrier and the placenta (EFSA 2026 [Ref 7]).

**Protein Binding:** >94% protein-bound in plasma.

**Half-life:** Approximately 18–32 hours with chronic dosing; shorter (~9 hours) with single dosing. The seed duration data (total: 1.5–4 hours) likely reflects the subjective effects duration, not the pharmacological half-life.

**Metabolism:** Primarily hepatic via CYP2C19 and CYP3A4 (Phase I), followed by glucuronidation via UGT1A9 and UGT2B7 (Phase II). Primary metabolites:
- 7-Hydroxy-CBD (7-OH-CBD): Active metabolite; pharmacologically relevant
- 7-Carboxy-CBD (7-COOH-CBD): Major abundant metabolite, less pharmacologically active
Substantial inter-individual variability in CBD metabolism due to CYP2C19 polymorphisms (Na and Lee 2025 [Ref 6]; Kalak et al. 2025 [Ref 44]).

**Lymphatic Transport:** A significant proportion of orally absorbed CBD (~11–20%) is transported via mesenteric lymph rather than portal circulation, partially bypassing first-pass metabolism (Rizov et al. 2026 [Ref 8 via pmid 41459703]).

---

## History

**1940:** Roger Adams and colleagues at the University of Illinois (USA) first isolated cannabidiol from cannabis. Alexander Todd at the University of Manchester (UK) isolated it independently at approximately the same time. The compound's structure was not determined at this time (Pertwee 2006 [Ref 34]; Zuardi 2008 [Ref 52]; Hanuš et al. 2016 [Ref 30]).

**1963:** Raphael Mechoulam and colleagues at the Hebrew University of Jerusalem elucidated the complete chemical structure of cannabidiol for the first time — before THC's structure was determined. This established the (1R,6R) stereochemistry of the natural enantiomer (Pertwee 2006 [Ref 34]; Zuardi 2008 [Ref 52]).

**1964:** Mechoulam identified Δ9-THC as the primary psychoactive constituent of cannabis, allowing CBD and THC to be clearly distinguished. Mechoulam's team subsequently confirmed CBD was non-psychoactive.

**1970s–1980s:** Early animal and human research began investigating CBD's anticonvulsant properties. Mechoulam, Carlini, and colleagues conducted small human trials showing CBD reduced seizures in a small cohort of treatment-resistant epilepsy patients. Early Zuardi group studies showed anxiolytic properties in humans (Zuardi 2008 [Ref 52]; Kalant 2001 [Ref 54]).

**2013–2015:** The public narrative around CBD shifted dramatically following CNN coverage of "Charlotte's Web" — a high-CBD cannabis preparation used for Dravet syndrome in a child named Charlotte Figi. This catalyzed large-scale clinical research through GW Pharmaceuticals.

**2017:** Devinsky et al. published the landmark Phase 3 RCT in the New England Journal of Medicine showing CBD significantly reduced seizures in Dravet syndrome (median 38.9% reduction vs. 13.3% placebo; p<0.001) (Devinsky et al. 2017 [Ref 45]).

**2018 (May–June):** Devinsky et al. published the GWPCARE3 trial showing CBD reduced drop seizures in Lennox-Gastaut syndrome (Devinsky et al. 2018 [Ref 55]). The FDA approved Epidiolex (GW Pharmaceuticals) on June 25, 2018 — the first cannabis plant-derived prescription medicine approved in the US — for Dravet syndrome and Lennox-Gastaut syndrome in patients ≥2 years.

**2018 (September):** The DEA placed FDA-approved CBD preparations (Epidiolex) into Schedule V of the Controlled Substances Act, the lowest abuse potential schedule. Hemp-derived CBD was effectively federally legalized via the Agriculture Improvement Act (2018 Farm Bill), which removed hemp (<0.3% THC) from Schedule I.

**2020:** The European Court of Justice ruled that CBD is not a narcotic under international conventions. GW Pharmaceuticals' Epidyolex received TGA approval in Australia (September 2020). EFSA began novel food assessments of CBD-containing food supplements.

**2021 (March):** FDA expanded Epidiolex approval to include tuberous sclerosis complex (TSC) in patients ≥1 year.

**2026:** The US Department of Justice/DEA finalized rescheduling of FDA-approved marijuana products to Schedule III (April 2026). CBD from hemp remains legal under Farm Bill provisions. EFSA published updated safety statement establishing a provisional safe dose of 0.0275 mg/kg bw/day (~2 mg/day for 70 kg adult) for food supplement formulations (Turck et al. 2026 [Ref 7]).

---

## Subjective Effects

CBD is non-intoxicating. No euphoria, perceptual distortion, or cognitive impairment occurs at clinical doses. Published descriptions from controlled studies describe the subjective experience primarily in terms of symptom reduction rather than intoxicating effects.

**From RCT and controlled study data:**

*Anxiety suppression:* The most consistently documented subjective effect is reduction of anxiety. Multiple RCTs and uncontrolled studies (17 RCTs per O'Sullivan et al. 2023 [Ref 11]) show CBD reduces anxiety in generalized social anxiety disorder, PTSD-related anxiety, and psychosis-related anxiety. Appiah-Kusi et al. (2020 [Ref via pmid 31915861]) documented stress response attenuation in subjects at clinical high risk of psychosis. CBD's anxiolytic mechanism operates via 5-HT₁A agonism and endocannabinoid augmentation (Blessing et al. 2015 [Ref 36]; Mandolini et al. 2018 [Ref 13]).

*Sedation:* Somnolence is the most commonly reported adverse effect in clinical epilepsy trials — reported in 22.6% of patients in an Italian real-world cohort (Iannone et al. 2021 [Ref 47]). Sedation is dose-dependent and represents a genuine subjective effect at therapeutic doses.

*Muscle relaxation:* Reported clinically and consistent with CBD's TRPV1 desensitization and CB1 NAM activity.

*Pain suppression:* CBD's analgesic properties are documented in animal models and some clinical data; mechanism involves TRPV1 desensitization and endocannabinoid augmentation. An updated Cochrane review (Ates et al. 2026 [Ref 41]) examined cannabis-based medicines for neuropathic pain. Whiting et al. (2015 [Ref 29]) found moderate evidence for cannabinoids in chronic pain but the CBD-specific evidence is less robust than for THC-containing preparations.

*Nausea suppression:* CBD reduces nausea via 5-HT₁A activation, demonstrated in rodent models by Rock et al. (2020 [Ref via pmid 32488349]) and DeVuono et al. (2022 [Ref via pmid 33998876]). CBD interferes with THC-induced nausea through a 5-HT₁A mechanism.

*Compulsive behavior reduction:* Documented in substance use contexts; CBD reduces methamphetamine relapse-seeking behavior in preclinical models (Umpierrez et al. 2026 [Ref via pmid 41605363]). Three RCTs show positive data for substance abuse (O'Sullivan et al. 2023 [Ref 11]).

*Mindfulness enhancement:* Subjectively reported by users; mechanistic basis may include anxiety reduction and endocannabinoid augmentation. No controlled studies directly measure "mindfulness enhancement" as a primary endpoint.

*Seizure threshold reduction (anticonvulsant):* Documented across multiple Phase 3 RCTs for Dravet syndrome, LGS, and TSC. The seed data lists "seizure-threshold-reduction" as an effect — this should be understood as CBD raises the seizure threshold (i.e., it is anticonvulsant), not lowers it. The effect slug name is potentially misleading for CBD's documented anticonvulsant action.

*Diarrhea:* Common adverse effect at clinical doses; reported in 11.9% of EAP patients (Iannone et al. 2021 [Ref 47]) and listed as an adverse effect in clinical trials (Crippa et al. 2022 [Ref 49]).

**Effect profile assessment (all 8 seed slugs are MISSING values):**
- diarrhea [body]: Common (>10% in clinical trials); mild intensity
- muscle-relaxation [body]: Moderate intensity; moderate frequency
- pain-suppression [body]: Mild-moderate intensity based on available evidence; variable frequency
- sedation [body]: Moderate intensity; common (>20% at therapeutic doses)
- seizure-threshold-reduction [body]: High intensity (primary therapeutic effect); specific to epilepsy indication — see Flag below
- anxiety-suppression [feeling]: Moderate-strong; the most consistently documented subjective effect
- compulsive-behavior-reduction [self]: Mild-moderate based on preclinical and limited clinical data
- mindfulness-enhancement [awareness]: Low evidence quality; user-reported, not confirmed in controlled trials

**Effect duration:** The seed total duration of 1.5–4 hours for oral administration is plausible for subjective effects (anxiolytic window) but pharmacological activity (via active metabolites) persists substantially longer given the 18–32 hour half-life. CBD's effects build over minutes to hours orally; come_up of 15–30 minutes is reasonable.

---

## Safety & Toxicity

**General Tolerability:** CBD is well-tolerated at a wide range of doses. In the COVID-19 RCT at 300 mg/day for 14 days, adverse effects were mild and transient with no significant difference from placebo (Crippa et al. 2022 [Ref 49]). The seed data statement "well-tolerated and shows little to no toxicity" is partially accurate at low-to-moderate doses but requires qualification at higher doses and in combination with other drugs.

**LD50:** No human LD50 data. Animal studies show an extremely high safety margin. CBD has been administered to humans at doses up to 1,500 mg/day in some studies without acute toxicity.

**Hepatotoxicity (SAFETY CRITICAL — FLAGGED):** The most significant safety concern for CBD is hepatotoxicity. Key findings:
- EFSA (2026 [Ref 7]) identified hepatotoxicity as a consistent endpoint in animal studies; benchmark dose modeling yielded a provisional safe dose of 0.0275 mg/kg bw/day (~2 mg/day for 70 kg adult) for food supplement formulations — substantially below clinical dosing ranges.
- In clinical epilepsy trials, elevated ALT was observed; confounded by valproate co-administration but appears to be a genuine CBD effect (Li et al. 2023 [Ref 14]).
- In HepaRG spheroids: EC50 cytotoxicity of 86.27 µM (24h) and 58.04 µM (72h) (Li et al. 2023 [Ref 14]).
- iPSC hepatocytes: transcriptomic point-of-departure (tPoD) 0.106 µM; CBD impairs CYP activity, mitochondrial membrane potential, and lipid accumulation at 0.1–3 µM (Campasino et al. 2024 [Ref via pmid 39233107]; Gao et al. 2024 [Ref via pmid 39004335]).
- At 60 mg/day x 7 days in healthy athletes: no hepatotoxic effects observed; CBD inhibited exercise-induced liver enzyme elevation (Isenmann et al. 2025 [Ref 31]).
- The LOAEL (lowest observed adverse effect level) in humans is approximately 300 mg/day (Isenmann et al. 2025 [Ref 31]).
- **Clinical recommendation:** Liver function monitoring is standard in patients on Epidiolex. Hepatotoxicity risk increases with valproate co-administration.

**Gastrointestinal:** Diarrhea (11.9% in EAP), nausea, and appetite changes are common at clinical doses (Iannone et al. 2021 [Ref 47]; Crippa et al. 2022 [Ref 49]).

**Somnolence/Sedation:** Dose-dependent; most common adverse effect in clinical trials (22.6% in Italian EAP [Ref 47]).

**Reproductive and Developmental Toxicity:** EFSA (2026 [Ref 7]) concluded that safety of CBD cannot be established for individuals under 25 years of age (except for approved medical indications), pregnant or lactating women, and those on concurrent medications. Animal studies show reproductive toxicity and neurodevelopmental effects following prenatal exposure.

**Endocrine Effects:** Animal studies reveal altered thyroid hormone levels and adrenal histopathology (EFSA 2026 [Ref 7]).

**Cardiovascular:** No significant cardiovascular adverse effects documented at therapeutic doses in adults (unlike THC which causes tachycardia). Lucas et al. (2018 [Ref 37]) note cardiovascular toxicity may occur via additive effects with sympathomimetic agents, but CBD alone has a favorable cardiovascular profile.

**Respiratory:** No respiratory depression documented. CBD is not a respiratory depressant.

**Immunotoxicity:** EFSA (2026 [Ref 7]) noted no studies addressing immunotoxicity directly, though CBD's interaction with immune pathways warrants caution. In vitro gene expression studies suggest immune regulatory pathway suppression.

---

## Harm Reduction

**Contraindications:**
1. Pregnancy and lactation — contraindicated due to placental transfer and developmental toxicity concerns (EFSA 2026 [Ref 7])
2. Severe hepatic impairment — increased hepatotoxicity risk
3. Concurrent valproate without liver function monitoring — elevated transaminase risk
4. Individuals under 25 (for non-medical use) — safety not established per EFSA
5. Concurrent strong CYP2C19 or CYP3A4-interacting medications without dose adjustment

**Drug Interactions (critical):**
- Clobazam: CBD inhibits CYP2C19 → elevated N-desmethylclobazam → consider clobazam dose reduction (Patsalos et al. 2020 [Ref 26]; Anderson et al. 2019 [Ref 27])
- Valproate: CBD + valproate → elevated liver enzymes; liver monitoring required; may need valproate dose reduction
- CYP2C19 substrates (SSRIs, PPIs, diazepam): CBD inhibits CYP2C19, increasing exposure (Anderson et al. 2021 [Ref 43])
- CYP3A4 substrates: CBD activates PXR → CYP3A4 induction → reduced substrate exposure (Lau and Chang 2026 [Ref 17])
- CNS depressants: Additive sedation

**Testing:** CBD products sold commercially vary widely in actual CBD content and may contain unlabeled THC. Third-party testing is important for consumer-grade products. Epidiolex is standardized at 100 mg/mL.

**Liver Monitoring:** Liver function tests should be obtained at baseline and at 1, 3, and 6 months during CBD treatment, and periodically thereafter, particularly in patients on valproate or other hepatotoxic medications (Iannone et al. 2021 [Ref 47]; Wechsler et al. 2024 [Ref 9]).

**"Start Low, Go Slow":** Lucas et al. (2018 [Ref 37]) recommend this approach for cannabis medicines. Clinical Epidiolex dosing starts at 2.5 mg/kg/day and is titrated to 5–10 mg/kg/day over weeks (Wechsler et al. 2024 [Ref 9]).

**Pediatric Caution:** CBD at therapeutic doses has documented clinical utility in children with severe epilepsy syndromes; however, long-term neurodevelopmental effects of CBD in children without epilepsy have not been established.

---

## Tolerance & Dependence

**Tolerance:** No pharmacological tolerance develops to CBD's anticonvulsant effects at therapeutic doses. CBD lacks tolerance and withdrawal effects at anticonvulsant doses (Del Pozo and Barker-Haliski 2023 [Ref 23]). This distinguishes CBD from THC, which produces tolerance through CB1 receptor downregulation/desensitization. Long-term open-label extension trials (GWPCARE5; Patel et al. 2021 [Ref 15]; Scheffer et al. 2021 [Ref 46]) show maintained seizure reduction without dose escalation over years of treatment.

**Dependence:** No physical or psychological dependence has been documented for CBD at any dose studied. Heal et al. (2024 [Ref 28]) concluded that "non-psychoactive cannabinoids do not produce intoxicating, cognitive or rewarding properties in humans." No withdrawal syndrome has been described after CBD discontinuation. Robson (2011 [Ref via pmid 21542664]) confirmed no physiological or psychological dependence with Sativex (CBD+THC) chronic use, attributing any dependence signals to the THC component.

**Abuse Potential:** The DEA's placement of Epidiolex in Schedule V (lowest abuse potential) in 2018 reflects the clinical and regulatory consensus that CBD has essentially no abuse potential. CBD produces no euphoria or intoxication.

**Cross-Tolerance:** No cross-tolerance data specifically for CBD. Unlike THC, CBD does not act as a CB1 agonist and would not be expected to produce CB1 cross-tolerance.

---

## Interactions

### CYP Enzyme Interactions (Pharmacokinetic)

**CYP2C19 Inhibition (clinically important):**
CBD is a clinically significant inhibitor of CYP2C19. This is responsible for the most important drug-drug interaction: CBD + clobazam produces elevated N-desmethylclobazam (active metabolite), requiring potential clobazam dose reduction (Patsalos et al. 2020 [Ref 26]; Anderson et al. 2019 [Ref 27]). CBD also increases citalopram exposure via CYP2C19 inhibition (Anderson et al. 2021 [Ref 43]). CYP2C19 genotype (poor vs. extensive metabolizers) substantially alters CBD's own pharmacokinetics (Kalak et al. 2025 [Ref 44]).

**CYP3A4 Induction (via PXR activation):**
CBD activates hPXR at concentrations relevant to therapeutic dosing, inducing CYP3A4 and potentially reducing plasma levels of CYP3A4 substrates (Lau and Chang 2026 [Ref 17]). However, Patsalos et al. (2020 [Ref 26]) found that when CYP3A4 was inhibited or induced, CBD exposure changed but CBD did not significantly affect CYP3A4 activity itself in clinical DDI trials — indicating context-dependence.

**CYP2C19 Inhibition leading to phenoconversion:** Chronic CBD use can convert a CYP2C19 extensive metabolizer phenotype to a poor metabolizer phenotype, substantially changing drug metabolism profiles (Kalak et al. 2025 [Ref 44]).

### Specific Drug Interactions

| Drug/Class | Interaction | Mechanism | Management |
|---|---|---|---|
| Clobazam | ↑ N-desmethylclobazam AUC | CYP2C19 inhibition | Monitor; reduce clobazam if ADRs appear |
| Valproate | ↑ Liver enzymes | Unknown (pharmacodynamic?) | LFT monitoring; may need VPA dose reduction |
| Citalopram / SSRIs | ↑ SSRI plasma levels | CYP2C19 inhibition | Monitor; dose adjustment possible |
| Stiripentol | Small ↑ CBD+stiripentol exposure | Bidirectional | Generally not clinically significant |
| CYP3A4 inducers (rifampicin, phenytoin) | ↓ CBD exposure | CYP3A4/CYP2C19 induction | May need CBD dose increase |
| CNS depressants | Additive sedation | Pharmacodynamic | Caution; start at lower doses |
| Sympathomimetics | Potential ↑ cardiovascular effects | Pharmacodynamic | Caution in cardiac patients |

*Sources: Patsalos et al. 2020 [Ref 26]; Anderson et al. 2019 [Ref 27]; Anderson et al. 2021 [Ref 43]; Lau and Chang 2026 [Ref 17]; Lucas et al. 2018 [Ref 37]*

**Serotonin Syndrome Risk:** No published cases of serotonin syndrome from CBD alone or CBD + SSRI have been identified. CBD is a 5-HT₁A partial agonist (not a serotonin reuptake inhibitor or strong agonist), which confers a low theoretical risk. The interaction with SSRIs is primarily pharmacokinetic (elevated SSRI levels via CYP2C19 inhibition), and this indirect mechanism could theoretically increase serotonergic tone. This remains an uncharacterized risk area.

---

## Legal Status

### United States
- **Hemp-derived CBD** (from cannabis with <0.3% THC): Federally legal under the Agriculture Improvement Act (2018 Farm Bill). However, FDA prohibits adding CBD to foods, beverages, or dietary supplements due to its drug status.
- **Epidiolex (pharmaceutical CBD):** Schedule V controlled substance (DEA, 2018); prescription required; approved for DS, LGS (2018), and TSC (2021).
- **Marijuana-derived CBD:** Previously Schedule I. As of April 23, 2026, the DOJ/DEA finalized rescheduling of FDA-approved marijuana products to Schedule III, easing some restrictions.
- *Sources: Mead 2019 [Ref 38]; web-retrieved legal sources [Ref 51]*

### United Kingdom
- CBD is legal for sale without prescription, provided it is not marketed as a medicine.
- CBD products must comply with novel food regulations; products >1 mg THC per package are restricted.
- Epidiolex is licensed and available on NHS prescription for severe pediatric epilepsy.
- *Source: web-retrieved [Ref 51]*

### European Union
- The European Court of Justice (2020) ruled CBD is not a narcotic under international conventions.
- Generally permitted, but regulations vary by member state regarding THC thresholds and product types.
- Novel food status applies across EU; authorized status still pending for food supplements as of 2026.
- *Source: web-retrieved [Ref 51]*

### Canada
- Regulated under the Cannabis Act (2018) by Health Canada. Requires licensed producers. CBD-containing products fall under cannabis regulation; hemp exemptions apply under threshold conditions.

### Australia
- CBD is Schedule 4 (prescription medicine) in practice.
- TGA down-scheduled low-dose CBD preparations to Schedule 3 (over-the-counter) in December 2020, but no OTC products have been registered as of 2026.
- Epidyolex TGA-approved September 2020 for LGS and DS (≥2 years).
- Epidyolex listed on Pharmaceutical Benefits Scheme (PBS) from May 1, 2021, for Dravet syndrome.
- *Source: web-retrieved [Ref 51]*

---

## Clinical Trials

### Landmark Completed Trials

**GWPCARE1 (NCT02091375, Phase 3):** CBD add-on for Dravet syndrome. Published as Devinsky et al. 2017 NEJM [Ref 45]. Median convulsive seizure frequency reduction: 38.9% vs. 13.3% placebo (p<0.001). Pivotal for FDA approval.

**GWPCARE3 (NCT02224210, Phase 3):** CBD add-on for Lennox-Gastaut syndrome (drop seizures). Published as Devinsky et al. 2018 NEJM [Ref 55]. Significant drop seizure reduction. Second pivotal trial for FDA approval.

**GWPCARE5 (NCT02224573, Phase 3 OLE):** Long-term open-label extension for DS and LGS. Published Patel et al. 2021 [Ref 15] and Scheffer et al. 2021 [Ref 46]. Sustained seizure reduction with maintained safety over years of treatment.

**GWPCARE6 (NCT02544763, Phase 3):** CBD for tuberous sclerosis complex. Post-hoc analysis published Wu et al. 2022 [Ref 48]. Led to TSC indication approval.

**CBD vs. Amisulpride in Schizophrenia (McGuire et al. 2018 [Ref 35]):** Multi-center Phase 2 RCT. CBD as adjunctive therapy in schizophrenia. CBD significantly improved positive psychotic symptoms; superior side-effect profile vs. amisulpride.

**CANDIDATE Study (NCT04467918):** CBD for mild-moderate COVID-19 (Crippa et al. 2022 [Ref 49]). Negative result; 300 mg/day CBD did not alter COVID-19 clinical course. Well tolerated.

### Selected Active/Recent Trials

**NCT04567784 (Phase 2, Completed):** CBD for opioid use disorder. Sponsor: Yasmin Hurd. Neuroimaging study.

**NCT04405414 (Completed):** Effects of CBD in patients with substance-related disorders (Nantes University Hospital).

**NCT04582591 (Phase 2, status unknown):** CBD for prevention of chemotherapy-induced peripheral neuropathy (Zealand University Hospital).

**CBD-CUD Study (Phase 3, Protocol Published 2025 [Ref via pmid 40096425]):** RCT comparing CBD to placebo for cannabis use disorder. Multi-site Australian trial.

**NCT02556008:** Cannabidiol for pediatric epilepsy compassionate use (UCLA).

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. Proceeding with standard research only.

---

## Gaps & Flags

### Data Gaps

1. **SMILES string:** Not provided in the brief's seed data. PubChem CID 644019 contains the SMILES, which should be retrieved and added to the DB record. ⚠️ FLAG: Generation agent should retrieve full SMILES from PubChem CID 644019 and populate the field.

2. **Binding affinity quantification (Ki/EC50 at CB1/CB2):** CBD's binding affinity at CB1 and CB2 is complex and context-dependent due to its NAM rather than direct agonist/antagonist mechanism. Ki values vary widely across studies and are not well-characterized as simple affinity constants. Generation agent should note this complexity rather than citing a specific Ki.

3. **Inhaled/sublingual pharmacokinetics:** The brief only lists oral ROA. Published data on inhaled CBD (higher bioavailability, faster onset) and sublingual bioavailability are available but not well-characterized in the sources retrieved. The seed data's "known ROAs: oral" should note that other ROAs are clinically and practically used.

4. **Duration data — offset/total vs. pharmacological half-life discrepancy:** The seed total duration of 1.5–4 hours does not reflect the pharmacological half-life of 18–32 hours. The generation agent should clarify that "duration" in the context of this article refers to the window of subjective effects, not pharmacological activity.

5. **Dose data for therapeutic (epilepsy) vs. recreational/wellness contexts:** The seed dose data (Threshold 2 mg, Light 5–15 mg, Common 15–30 mg) reflects wellness/anxiety use patterns. Clinical epilepsy doses are 5–25 mg/kg/day (Wechsler et al. 2024 [Ref 9]), which for adults translates to 350–1750 mg/day — orders of magnitude higher. Generation agent should distinguish these contexts explicitly.

6. **Physical properties:** Melting point, exact water solubility, and vapor pressure data for CBD were not retrievable from the literature search conducted. These can be found in chemical databases but were not reported in the PubMed literature retrieved.

7. **Human PK studies with specific Tmax values:** The come_up of 15–30 minutes in seed data lacks a primary source. The Tmax for oral CBD is typically longer (1.5–5 hours depending on formulation and fed/fasted state). The come_up may reflect the onset of subjective effects rather than Tmax. ⚠️ FLAG: The seed come_up value needs editorial review.

### Safety-Critical Flags

1. ⚠️ **EFSA provisional safe dose for food supplements is 0.0275 mg/kg/day (~2 mg/day for 70 kg adult)** — far below the seed data's "Common: 15–30 mg" dose range. This is not a contradiction (the EFSA value applies to food supplement formulations, not pharmaceutical use), but the generation article should include this context with clear framing.

2. ⚠️ **Hepatotoxicity risk not mentioned in existing seed summary or toxicity data.** The seed data states "well-tolerated and shows little to no toxicity." This requires substantial qualification: liver toxicity concerns are a major regulatory and clinical issue. The generation agent MUST include hepatotoxicity and the requirement for liver function monitoring.

3. ⚠️ **"Seizure threshold reduction" effect slug — semantic issue:** The slug name implies CBD lowers the seizure threshold (i.e., makes seizures more likely). CBD's documented action is anticonvulsant — it raises the seizure threshold. The generation agent should be aware of this potential confusion and describe the effect accurately (CBD's anticonvulsant action, not a proconvulsant one).

4. ⚠️ **Contraindications field is blank in seed data.** Multiple contraindications are now established from the literature: pregnancy, lactation, severe hepatic impairment, concurrent valproate without monitoring, CYP2C19-substrate medications. These must be populated.

5. ⚠️ **Interactions field is blank in seed data.** Multiple clinically significant drug interactions documented (see Interactions section above). Critical for harm reduction. Generation agent must populate.

6. ⚠️ **Tolerance data is blank.** Evidence clearly shows no tolerance or dependence; this should be populated explicitly.

7. **Canada legal status:** Specific details of CBD's regulation under the Canadian Cannabis Act were not retrieved in this research session and should be verified before publication.